FAH, fumarylacetoacetate hydrolase, 2184

N. diseases: 78; N. variants: 56
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.240 Biomarker disease BEFREE In this study, we investigated whether fumarylacetoacetate hydrolase deficient (FAH<sup>-/-</sup>) pigs, a novel large-animal model of HT1, develop fibrosis and cirrhosis characteristic of the human disease. 27855279 2017
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.240 Biomarker disease BEFREE Moreover, the highly efficient repopulation of hepatocytes in Fah(-/-) livers prevented the progression of liver fibrosis to cirrhosis and in turn restored liver architecture. 27510266 2016
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.240 GeneticVariation disease BEFREE Pathogenic variants in FAH cause TYRSN1, which induces cirrhosis and can progress to hepatocellular carcinoma (HCC). 27397503 2016
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.240 Biomarker disease RGD Moreover, the highly efficient repopulation of hepatocytes in Fah(-/-) livers prevented the progression of liver fibrosis to cirrhosis and in turn restored liver architecture. 27510266 2016
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.240 Biomarker disease BEFREE Tyrosinaemia I (fumarylacetoacetate hydrolase deficiency) is an autosomal recessive inborn error of tyrosine metabolism that produces liver failure in infancy or a more chronic course of liver disease with cirrhosis, often complicated by hepatocellular carcinoma, in childhood or early adolescence. 11196105 2000